Search Results for: insulin

Despite its discovery nearly 100 years ago, insulin’s list price has been going up, not down. Schaeffer Center researchers analyzes the flow of money across all distribution system participants—manufacturers, wholesalers, pharmacies, pharmacy benefit managers (PBMs), and health plans.

Schaeffer Center researchers examined how use of insulin changes as cost-sharing fluctuates over the course of the year for Medicare Part D beneficiaries.

Publicly insured individuals who are most likely to benefit from new diabetes and obesity drugs are less likely to get them than those with private insurance.

As policymakers consider reforms to the prescription drug supply chain, they should keep five principles in mind to ensure better outcomes for patients.

In health care, the term “value” gets lobbed about quite loosely. It is easy to forget that centuries of economic thought have gone into rigorously examining how worth is determined in a marketplace.

Drug costs can be driven down if market forces are allowed to target those profits, but first everyone needs to know what is being charged, and by whom to whom.

Medicare released the list of the first 10 drugs subject to price negotiations under the Inflation Reduction Act (IRA), aiming to reduce drug costs for Medicare enrollees and taxpayers.

The shortages, which have been going on for years, have typically affected only low-cost generics rather than profitable brand-name drugs.

One potential path for reducing Medicare Advantage (MA) overpayments from favorable selection is reforming the current administered payment approaches linking spending in fee-for-service (FFS) to MA rates.

This paper provides three recommendations to steer the potential effects of the IRA toward its goal of improving patient access while encouraging innovation.